Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 20Unknown 12Recruiting 9Terminated 7Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Pelvic Mass 1Neoplasms 1Hemorrhage 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Tranexamic Acid × Clear all
NCT03128866 2026-03-05

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
80 enrolled

Pelvic Mass

NCT02261415 2022-10-26

HeLiX

Sunnybrook Health Sciences Centre

Phase 3 Active not recruiting
1,386 enrolled

Hemorrhage, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡